Details of the Drug

General Information of Drug (ID: DMKXY2R)

Drug Name
Ibutilide
Synonyms
Corvert; Ibutilida; Ibutilidum; Butilide fumarate; IBUTILIDE FUMARATE; Ibutilide Fumarate [USAN]; U 70226E; U82208E; U82209E; Corvert (TN); Ibutilida [INN-Spanish]; Ibutilide (INN); Ibutilide [BAN:INN]; Ibutilide [INN:BAN]; Ibutilide fumarate (USAN); Ibutilidum [INN-Latin]; U-70226E; U-82208E; U-82209E; Ibutilide, (+-)-isomer; N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide; Ibutilide, fumarate salt (2:1), (+-)-isomer; N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide; N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (E)-2-butenedioate (2:1) (salt); Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-, (E)-2-butenedioate (2:1) (salt); Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-,(E)-2-butenedioate (2:1) (salt); (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfoanilide (E)-2-butenedioate (2:1); (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfonanilide fumarate (2:1) (salt); (+-)-N-(4-(4-(Ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide (E)-butenedioate
Indication
Disease Entry ICD 11 Status REF
Atrial fibrillation BC81.3 Approved [1], [2]
Therapeutic Class
Antiarrhythmic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 384.6
Topological Polar Surface Area (xlogp) 4
Rotatable Bond Count (rotbonds) 14
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption
The drug is rapid after intravenous injection [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The clearance of drug is 29 mL/min/kg [5]
Elimination
7% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 6 hours (ranges from 2 - 12 h) [6]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.3389 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.6% [6]
Vd
The volume of distribution (Vd) of drug is 11 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 100 mg/mL [4]
Chemical Identifiers
Formula
C20H36N2O3S
IUPAC Name
N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide
Canonical SMILES
CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O
InChI
InChI=1S/C20H36N2O3S/c1-4-6-7-8-9-16-22(5-2)17-10-11-20(23)18-12-14-19(15-13-18)21-26(3,24)25/h12-15,20-21,23H,4-11,16-17H2,1-3H3
InChIKey
ALOBUEHUHMBRLE-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
60753
ChEBI ID
CHEBI:5856
CAS Number
122647-31-8
DrugBank ID
DB00308
TTD ID
D02MLW

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Potassium channel unspecific (KC) TT1VOHK NOUNIPROTAC Modulator [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ibutilide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Ibutilide and Adenosine. Supraventricular tachyarrhythmia [BC81] [13]
Coadministration of a Drug Treating the Disease Different from Ibutilide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Ibutilide and Ivosidenib. Acute myeloid leukaemia [2A60] [14]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Ibutilide and Midostaurin. Acute myeloid leukaemia [2A60] [15]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Ibutilide and Idarubicin. Acute myeloid leukaemia [2A60] [15]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Ibutilide and Daunorubicin. Acute myeloid leukaemia [2A60] [15]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Ibutilide and Arn-509. Acute myeloid leukaemia [2A60] [15]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Ibutilide and Gilteritinib. Acute myeloid leukaemia [2A60] [15]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Ibutilide and Oliceridine. Acute pain [MG31] [16]
Terfenadine DM4KLPT Major Increased risk of prolong QT interval by the combination of Ibutilide and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [15]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Ibutilide and Tacrine. Alzheimer disease [8A20] [15]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Ibutilide and Galantamine. Alzheimer disease [8A20] [15]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Ibutilide and Rivastigmine. Alzheimer disease [8A20] [15]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Ibutilide and Donepezil. Alzheimer disease [8A20] [15]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Ibutilide and Metronidazole. Amoebiasis [1A36] [17]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Ibutilide and Ivabradine. Angina pectoris [BA40] [18]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Ibutilide and Bepridil. Angina pectoris [BA40] [15]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Ibutilide and Dronedarone. Angina pectoris [BA40] [15]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Ibutilide and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [15]
Hydroxyzine DMF8Y74 Major Increased risk of prolong QT interval by the combination of Ibutilide and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [15]
Promazine DMZAL7W Major Increased risk of prolong QT interval by the combination of Ibutilide and Promazine. Appearance/behaviour symptom [MB23] [15]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Ibutilide and Cilostazol. Arterial occlusive disease [BD40] [15]
Voriconazole DMAOL2S Major Increased risk of prolong QT interval by the combination of Ibutilide and Voriconazole. Aspergillosis [1F20] [15]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Ibutilide and Posaconazole. Aspergillosis [1F20] [15]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Ibutilide and Levalbuterol. Asthma [CA23] [19]
Terbutaline DMD4381 Major Increased risk of prolong QT interval by the combination of Ibutilide and Terbutaline. Asthma [CA23] [20]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Ibutilide and Pirbuterol. Asthma [CA23] [20]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Ibutilide and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [15]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Ibutilide and Ofloxacin. Bacterial infection [1A00-1C4Z] [15]
Ciprofloxacin XR DM2NLS9 Major Increased risk of prolong QT interval by the combination of Ibutilide and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [15]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Ibutilide and Clarithromycin. Bacterial infection [1A00-1C4Z] [21]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Ibutilide and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [15]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Ibutilide and Sparfloxacin. Bacterial infection [1A00-1C4Z] [22]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Ibutilide and Gemifloxacin. Bacterial infection [1A00-1C4Z] [15]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Ibutilide and Norfloxacin. Bacterial infection [1A00-1C4Z] [15]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Ibutilide and Levofloxacin. Bacterial infection [1A00-1C4Z] [15]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Ibutilide and Lomefloxacin. Bacterial infection [1A00-1C4Z] [15]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Ibutilide and Telithromycin. Bacterial infection [1A00-1C4Z] [15]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Ibutilide and Retigabine. Behcet disease [4A62] [15]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Ibutilide and Loperamide. Bowel habit change [ME05] [23]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Ibutilide and Eribulin. Breast cancer [2C60-2C6Y] [15]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Ibutilide and Lapatinib. Breast cancer [2C60-2C6Y] [15]
Tamoxifen DMLB0EZ Major Increased risk of prolong QT interval by the combination of Ibutilide and Tamoxifen. Breast cancer [2C60-2C6Y] [15]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Ibutilide and Toremifene. Breast cancer [2C60-2C6Y] [15]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Ibutilide and Bosutinib. Breast cancer [2C60-2C6Y] [15]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Ibutilide and Grepafloxacin. Bronchitis [CA20] [22]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Ibutilide and Sotalol. Cardiac arrhythmia [BC9Z] [15]
Iodipamide DMXIQYS Moderate Increased risk of ventricular arrhythmias by the combination of Ibutilide and Iodipamide. Cholelithiasis [DC11] [24]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Ibutilide and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [15]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Ibutilide and Olodaterol. Chronic obstructive pulmonary disease [CA22] [20]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Ibutilide and Vilanterol. Chronic obstructive pulmonary disease [CA22] [19]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Ibutilide and Salmeterol. Chronic obstructive pulmonary disease [CA22] [20]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Ibutilide and Indacaterol. Chronic obstructive pulmonary disease [CA22] [20]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Ibutilide and Arformoterol. Chronic obstructive pulmonary disease [CA22] [20]
Oxaliplatin DMQNWRD Major Increased risk of prolong QT interval by the combination of Ibutilide and Oxaliplatin. Colorectal cancer [2B91] [15]
Levobupivacaine DM783CH Moderate Increased risk of atrioventricular block by the combination of Ibutilide and Levobupivacaine. Corneal disease [9A76-9A78] [25]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Ibutilide and Halothane. Corneal disease [9A76-9A78] [15]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Ibutilide and Propofol. Corneal disease [9A76-9A78] [26]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Ibutilide and Sevoflurane. Corneal disease [9A76-9A78] [15]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Ibutilide and Probucol. Coronary atherosclerosis [BA80] [15]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Ibutilide and Methadone. Cough [MD12] [15]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Ibutilide and Clofazimine. Crohn disease [DD70] [15]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Ibutilide and Mifepristone. Cushing syndrome [5A70] [15]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Ibutilide and Pasireotide. Cushing syndrome [5A70] [15]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Ibutilide and Osilodrostat. Cushing syndrome [5A70] [15]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Ibutilide and Sertraline. Depression [6A70-6A7Z] [15]
Trimipramine DM1SC8M Major Increased risk of prolong QT interval by the combination of Ibutilide and Trimipramine. Depression [6A70-6A7Z] [15]
Imipramine DM2NUH3 Major Increased risk of prolong QT interval by the combination of Ibutilide and Imipramine. Depression [6A70-6A7Z] [15]
Fluoxetine DM3PD2C Major Increased risk of prolong QT interval by the combination of Ibutilide and Fluoxetine. Depression [6A70-6A7Z] [15]
Nortriptyline DM4KDYJ Major Increased risk of prolong QT interval by the combination of Ibutilide and Nortriptyline. Depression [6A70-6A7Z] [15]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Ibutilide and Escitalopram. Depression [6A70-6A7Z] [15]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Ibutilide and Clomipramine. Depression [6A70-6A7Z] [15]
Trazodone DMK1GBJ Major Increased risk of prolong QT interval by the combination of Ibutilide and Trazodone. Depression [6A70-6A7Z] [15]
Amitriptyline DMK7F9S Major Increased risk of prolong QT interval by the combination of Ibutilide and Amitriptyline. Depression [6A70-6A7Z] [15]
Amoxapine DMKITQE Major Increased risk of prolong QT interval by the combination of Ibutilide and Amoxapine. Depression [6A70-6A7Z] [15]
Mirtazapine DML53ZJ Major Increased risk of prolong QT interval by the combination of Ibutilide and Mirtazapine. Depression [6A70-6A7Z] [15]
Protriptyline DMNHTZI Major Increased risk of prolong QT interval by the combination of Ibutilide and Protriptyline. Depression [6A70-6A7Z] [15]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Ibutilide and Doxepin. Depression [6A70-6A7Z] [15]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Ibutilide and Maprotiline. Depression [6A70-6A7Z] [15]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Ibutilide and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [15]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Ibutilide and Deutetrabenazine. Dystonic disorder [8A02] [15]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Ibutilide and Ingrezza. Dystonic disorder [8A02] [15]
Diphenhydramine DMKQTBA Moderate Increased risk of prolong QT interval by the combination of Ibutilide and Diphenhydramine. Episodic vestibular syndrome [AB31] [17]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Ibutilide and Solifenacin. Functional bladder disorder [GC50] [15]
Pentamidine DMHZJCG Major Increased risk of prolong QT interval by the combination of Ibutilide and Pentamidine. Fungal infection [1F29-1F2F] [15]
Ketoconazole DMPZI3Q Major Increased risk of prolong QT interval by the combination of Ibutilide and Ketoconazole. Fungal infection [1F29-1F2F] [15]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Ibutilide and Cisapride. Gastro-oesophageal reflux disease [DA22] [15]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Ibutilide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [15]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Ibutilide and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [15]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Ibutilide and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [27]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Ibutilide and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [28]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Ibutilide and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [17]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Ibutilide and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [15]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Ibutilide and Polyethylene glycol. Irritable bowel syndrome [DD91] [29]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Ibutilide and Phenolphthalein. Irritable bowel syndrome [DD91] [15]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Ibutilide and Crizotinib. Lung cancer [2C25] [15]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Ibutilide and Ceritinib. Lung cancer [2C25] [15]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Ibutilide and Osimertinib. Lung cancer [2C25] [15]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Ibutilide and Selpercatinib. Lung cancer [2C25] [15]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Ibutilide and Lumefantrine. Malaria [1F40-1F45] [17]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Ibutilide and Halofantrine. Malaria [1F40-1F45] [30]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Ibutilide and Chloroquine. Malaria [1F40-1F45] [31]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Ibutilide and Hydroxychloroquine. Malaria [1F40-1F45] [31]
Quinine DMSWYF5 Major Increased risk of prolong QT interval by the combination of Ibutilide and Quinine. Malaria [1F40-1F45] [15]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Ibutilide and Primaquine. Malaria [1F40-1F45] [15]
Mefloquine DMWT905 Major Increased risk of prolong QT interval by the combination of Ibutilide and Mefloquine. Malaria [1F40-1F45] [15]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Ibutilide and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [15]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Ibutilide and Arsenic trioxide. Mature B-cell lymphoma [2A85] [32]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Ibutilide and Vemurafenib. Melanoma [2C30] [15]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Ibutilide and LGX818. Melanoma [2C30] [15]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Ibutilide and Thalidomide. Multiple myeloma [2A83] [17]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Ibutilide and Siponimod. Multiple sclerosis [8A40] [17]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Ibutilide and Ozanimod. Multiple sclerosis [8A40] [33]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Ibutilide and Romidepsin. Mycosis fungoides [2B01] [15]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Ibutilide and Nilotinib. Myeloproliferative neoplasm [2A20] [15]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Ibutilide and Dasatinib. Myeloproliferative neoplasm [2A20] [15]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Ibutilide and Droperidol. Nausea/vomiting [MD90] [15]
Dimenhydrinate DM264B3 Moderate Increased risk of prolong QT interval by the combination of Ibutilide and Dimenhydrinate. Nausea/vomiting [MD90] [17]
Prochlorperazine DM53SRA Major Increased risk of prolong QT interval by the combination of Ibutilide and Prochlorperazine. Nausea/vomiting [MD90] [15]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Ibutilide and Promethazine. Nausea/vomiting [MD90] [15]
Palonosetron DMBHMOX Major Increased risk of prolong QT interval by the combination of Ibutilide and Palonosetron. Nausea/vomiting [MD90] [15]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Ibutilide and Granisetron. Nausea/vomiting [MD90] [15]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Ibutilide and Dolasetron. Nausea/vomiting [MD90] [15]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Ibutilide and Ondansetron. Nausea/vomiting [MD90] [15]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Ibutilide and Entrectinib. Non-small cell lung cancer [2C25] [15]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Ibutilide and Levomethadyl Acetate. Opioid use disorder [6C43] [18]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Ibutilide and Lofexidine. Opioid use disorder [6C43] [15]
Dextropropoxyphene DM23HCX Major Increased risk of prolong QT interval by the combination of Ibutilide and Dextropropoxyphene. Pain [MG30-MG3Z] [17]
Prilocaine DMI7DZ2 Moderate Increased risk of atrioventricular block by the combination of Ibutilide and Prilocaine. Pain [MG30-MG3Z] [25]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Ibutilide and Buprenorphine. Pain [MG30-MG3Z] [15]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Ibutilide and Triclabendazole. Parasitic worm infestation [1F90] [15]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Ibutilide and Pimavanserin. Parkinsonism [8A00] [15]
Apomorphine DMX38HQ Major Increased risk of prolong QT interval by the combination of Ibutilide and Apomorphine. Parkinsonism [8A00] [15]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Ibutilide and Macimorelin. Pituitary gland disorder [5A60-5A61] [34]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Ibutilide and Lefamulin. Pneumonia [CA40] [35]
Ritodrine DM4V6RL Major Increased risk of ventricular arrhythmias by the combination of Ibutilide and Ritodrine. Preterm labour/delivery [JB00] [20]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Ibutilide and Degarelix. Prostate cancer [2C82] [15]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Ibutilide and ABIRATERONE. Prostate cancer [2C82] [15]
Nilutamide DMFN07X Major Increased risk of prolong QT interval by the combination of Ibutilide and Nilutamide. Prostate cancer [2C82] [15]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Ibutilide and Enzalutamide. Prostate cancer [2C82] [15]
Flutamide DMK0O7U Major Increased risk of prolong QT interval by the combination of Ibutilide and Flutamide. Prostate cancer [2C82] [15]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Ibutilide and Relugolix. Prostate cancer [2C82] [15]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Ibutilide and Bicalutamide. Prostate cancer [2C82] [15]
Alfuzosin DMZVMKF Major Increased risk of prolong QT interval by the combination of Ibutilide and Alfuzosin. Prostate hyperplasia [GA90] [15]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Ibutilide and Levomepromazine. Psychotic disorder [6A20-6A25] [15]
Fluphenazine DMIT8LX Major Increased risk of prolong QT interval by the combination of Ibutilide and Fluphenazine. Psychotic disorder [6A20-6A25] [15]
Triflupromazine DMKFQJP Major Increased risk of prolong QT interval by the combination of Ibutilide and Triflupromazine. Psychotic disorder [6A20-6A25] [15]
Sorafenib DMS8IFC Major Increased risk of prolong QT interval by the combination of Ibutilide and Sorafenib. Renal cell carcinoma [2C90] [15]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Ibutilide and Gatifloxacin. Respiratory infection [CA07-CA4Z] [15]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Ibutilide and Quetiapine. Schizophrenia [6A20] [15]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Ibutilide and Mesoridazine. Schizophrenia [6A20] [15]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Ibutilide and Thioridazine. Schizophrenia [6A20] [15]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Ibutilide and Aripiprazole. Schizophrenia [6A20] [17]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Ibutilide and Iloperidone. Schizophrenia [6A20] [15]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Ibutilide and Paliperidone. Schizophrenia [6A20] [15]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Ibutilide and Haloperidol. Schizophrenia [6A20] [15]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Ibutilide and Perphenazine. Schizophrenia [6A20] [15]
Chlorpromazine DMBGZI3 Major Increased risk of prolong QT interval by the combination of Ibutilide and Chlorpromazine. Schizophrenia [6A20] [15]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Ibutilide and Clozapine. Schizophrenia [6A20] [15]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Ibutilide and Trifluoperazine. Schizophrenia [6A20] [15]
Risperidone DMN6DXL Major Increased risk of prolong QT interval by the combination of Ibutilide and Risperidone. Schizophrenia [6A20] [15]
Olanzapine DMPFN6Y Moderate Increased risk of prolong QT interval by the combination of Ibutilide and Olanzapine. Schizophrenia [6A20] [17]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Ibutilide and Amisulpride. Schizophrenia [6A20] [17]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Ibutilide and Asenapine. Schizophrenia [6A20] [15]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Ibutilide and Pimozide. Schizophrenia [6A20] [18]
Mepivacaine DMH2NMY Moderate Increased risk of atrioventricular block by the combination of Ibutilide and Mepivacaine. Sensation disturbance [MB40] [25]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Ibutilide and Vardenafil. Sexual dysfunction [HA00-HA01] [15]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Ibutilide and LEE011. Solid tumour/cancer [2A00-2F9Z] [15]
Epirubicin DMPDW6T Major Increased risk of prolong QT interval by the combination of Ibutilide and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [15]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Ibutilide and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [15]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Ibutilide and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [15]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Ibutilide and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [15]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Ibutilide and Pitolisant. Somnolence [MG42] [15]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Ibutilide and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [15]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Ibutilide and Lenvatinib. Thyroid cancer [2D10] [15]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Ibutilide and Cabozantinib. Thyroid cancer [2D10] [15]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Ibutilide and Papaverine. Tonus and reflex abnormality [MB47] [36]
Tizanidine DMR2IQ4 Major Increased risk of prolong QT interval by the combination of Ibutilide and Tizanidine. Tonus and reflex abnormality [MB47] [15]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Ibutilide and Tacrolimus. Transplant rejection [NE84] [15]
Astemizole DM2HN6Q Major Increased risk of prolong QT interval by the combination of Ibutilide and Astemizole. Vasomotor/allergic rhinitis [CA08] [15]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Ibutilide and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [17]
Bretylium DM1FX74 Major Increased risk of prolong QT interval by the combination of Ibutilide and Bretylium. Ventricular tachyarrhythmia [BC71] [15]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Ibutilide and Propafenone. Ventricular tachyarrhythmia [BC71] [37]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Ibutilide and Flecainide. Ventricular tachyarrhythmia [BC71] [15]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Ibutilide and Amiodarone. Ventricular tachyarrhythmia [BC71] [15]
⏷ Show the Full List of 183 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7200).
2 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
10 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
11 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
12 Azimilide. Drugs. 2000 Feb;59(2):271-7; discussion 278-9.
13 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
14 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
15 Canadian Pharmacists Association.
16 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
17 Cerner Multum, Inc. "Australian Product Information.".
18 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
20 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
21 Gitler B, Berger LS, Buffa SD "Torsades de pointes induced by erythromycin." Chest 105 (1994): 368-72. [PMID: 8306730]
22 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
23 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
24 Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U "Iohexol contrast medium induces QT prolongation in amiodarone patients." Br J Clin Pharmacol 58 (2004): 96-98. [PMID: 15206999]
25 Keidar S, Grenadier E, Palant A "Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration." Am Heart J 104 (1982): 1384-5. [PMID: 7148661]
26 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
27 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
28 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
29 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
30 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
31 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
32 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
33 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
34 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
35 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
36 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
37 Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985): 424-8. [PMID: 4043097]